Wall St futures flat amid US-China trade jitters; bank earnings in focus
NEW YORK - Anavex Life Sciences Corp. (NASDAQ:AVXL), currently valued at $774 million and showing a remarkable 59% return over the past year according to InvestingPro, announced Thursday the successful development of a once-daily oral tablet formulation for its ANAVEX3-71 program, following positive results from a Phase 1b clinical trial.
The ANAVEX3-71-002 trial achieved its primary endpoint, demonstrating safety and tolerability in both male and female adults. According to the company, the modified-release oral tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule. With a strong current ratio of 8.93, InvestingPro data shows the company maintains ample liquidity to support its clinical development programs.
The completed open-label, randomized study evaluated pharmacokinetics and safety of both immediate and modified release formulations in healthy adults 18 years or older. Results showed a pharmacokinetic profile supporting once-daily dosing with a safety profile consistent with prior ANAVEX3-71 studies.
"We are pleased to see that our latest ANAVEX3-71 formulation study meets our expectations for safety and tolerability," said Christopher U. Missling, President and CEO of Anavex.
ANAVEX3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. The company states this mechanism of action offers potential to treat all symptom domains of schizophrenia without the side effects of standard antipsychotics.
The drug candidate has previously been studied in healthy volunteers and in a Phase 2 study identified as ANAVEX3-71-SZ-001.
Anavex Life Sciences is focused on developing treatments for various neurological conditions including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and Rett syndrome.
This information is based on a press release statement from the company.
In other recent news, Anavex Life Sciences Corp. reported its financial results for the third quarter of 2025, posting a net loss of $13.2 million or $0.16 per share, which slightly missed the expected earnings per share (EPS) forecast of -$0.1457. The company maintains a robust cash position of $101.2 million with no debt, despite the missed EPS expectations. Anavex Life Sciences also announced positive topline results from its Phase 2 clinical study of ANAVEX®3-71 for treating schizophrenia, achieving the primary endpoint of safety and tolerability with no serious adverse events reported. This study was conducted with adults on stable antipsychotic medication, and the safety profile was consistent with prior studies. Additionally, H.C. Wainwright reiterated a Buy rating for Anavex Life Sciences, maintaining a price target of $42.00, following new clinical data from its Phase 2b/3 trial of blarcamesine in Alzheimer’s disease. The data showed minimal decline in early Alzheimer’s patients taking blarcamesine. The firm also noted positive findings from a peer-reviewed study on blarcamesine, which demonstrated the prevention of memory impairment in an Alzheimer’s disease model. These developments highlight Anavex Life Sciences’ ongoing research efforts and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.